• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

环丙沙星两种给药方案在囊性纤维化患者为期两周的治疗试验中的药代动力学。

Pharmacokinetics of two dosage regimens of ciprofloxacin during a two-week therapeutic trial in patients with cystic fibrosis.

作者信息

Stutman H R, Shalit I, Marks M I, Greenwood R, Chartrand S A, Hilman B C

出版信息

Am J Med. 1987 Apr 27;82(4A):142-5.

PMID:3555028
Abstract

Twenty-nine adult patients with cystic fibrosis received 750 or 1,000 mg of ciprofloxacin orally every 12 hours for two weeks. Pharmacokinetic data were collected on Days 1, 7, and 14. Pharmacokinetic analyses revealed minor differences between the dosage regimens, and results were similar on the first, seventh, and last day of therapy. Means for peak serum concentration (3.1 to 5.0 micrograms/ml), elimination half-life (4.8 to 5.3 hours), area under the time-concentration curve, and serum clearance (36.8 to 44.5 liter/hour) were similar to previously reported results for patients without cystic fibrosis. Sputum concentrations approximated serum values.

摘要

29名成年囊性纤维化患者每12小时口服750毫克或1000毫克环丙沙星,持续两周。在第1天、第7天和第14天收集药代动力学数据。药代动力学分析显示不同给药方案之间存在微小差异,治疗第1天、第7天和最后一天的结果相似。血清峰浓度(3.1至5.0微克/毫升)、消除半衰期(4.8至5.3小时)、时间-浓度曲线下面积和血清清除率(36.8至44.5升/小时)的平均值与先前报道的非囊性纤维化患者的结果相似。痰液浓度接近血清值。

相似文献

1
Pharmacokinetics of two dosage regimens of ciprofloxacin during a two-week therapeutic trial in patients with cystic fibrosis.环丙沙星两种给药方案在囊性纤维化患者为期两周的治疗试验中的药代动力学。
Am J Med. 1987 Apr 27;82(4A):142-5.
2
Ciprofloxacin monotherapy for acute pulmonary exacerbations of cystic fibrosis.环丙沙星单药治疗囊性纤维化急性肺部加重期
Am J Med. 1987 Apr 27;82(4A):174-9.
3
Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.群体药代动力学及应用蒙特卡洛模拟评估目前推荐的囊性纤维化成年患者环丙沙星给药方案
Antimicrob Agents Chemother. 2001 Dec;45(12):3468-73. doi: 10.1128/AAC.45.12.3468-3473.2001.
4
Randomized study of two dosage regimens of ciprofloxacin for treating chronic bronchopulmonary infection in patients with cystic fibrosis.环丙沙星两种给药方案治疗囊性纤维化患者慢性支气管肺部感染的随机研究。
Am J Med. 1987 Apr 27;82(4A):189-95.
5
Pharmacokinetics of ciprofloxacin in acutely ill and convalescent elderly patients.
Am J Med. 1987 Apr 27;82(4A):124-9.
6
Clinical efficacy of ciprofloxacin in lower respiratory tract infections.
Scand J Infect Dis Suppl. 1989;60:89-97.
7
Pharmacokinetics of azithromycin in plasma, blood, polymorphonuclear neutrophils and sputum during long-term therapy in patients with cystic fibrosis.阿奇霉素在囊性纤维化患者长期治疗期间血浆、血液、多形核中性粒细胞和痰液中的药代动力学。
Ther Drug Monit. 2006 Apr;28(2):219-25. doi: 10.1097/01.ftd.0000195617.69721.a5.
8
Effect of ciprofloxacin on fecal flora of patients with cystic fibrosis and other patients treated with oral ciprofloxacin.
Am J Med. 1987 Apr 27;82(4A):336-8.
9
Dual individualization of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections.
Am J Med. 1987 Apr 27;82(4A):352-6.
10
Pharmacokinetics and sputum penetration of ciprofloxacin in patients with cystic fibrosis.环丙沙星在囊性纤维化患者中的药代动力学及痰液穿透性
Antimicrob Agents Chemother. 1986 Oct;30(4):614-6. doi: 10.1128/AAC.30.4.614.

引用本文的文献

1
Interventions for the eradication of meticillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis.针对囊性纤维化患者中耐甲氧西林金黄色葡萄球菌(MRSA)的清除干预措施。
Cochrane Database Syst Rev. 2022 Dec 13;12(12):CD009650. doi: 10.1002/14651858.CD009650.pub5.
2
Eradication therapy for Burkholderia cepacia complex in people with cystic fibrosis.囊性纤维化患者中洋葱伯克霍尔德菌复合体的根除治疗。
Cochrane Database Syst Rev. 2019 Apr 18;4(4):CD009876. doi: 10.1002/14651858.CD009876.pub4.
3
Treatment for chronic methicillin-sensitive Staphylococcus aureus pulmonary infection in people with cystic fibrosis.
囊性纤维化患者慢性甲氧西林敏感金黄色葡萄球菌肺部感染的治疗
Cochrane Database Syst Rev. 2018 Jul 27;7(7):CD011581. doi: 10.1002/14651858.CD011581.pub3.
4
Interventions for the eradication of meticillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis.根除囊性纤维化患者体内耐甲氧西林金黄色葡萄球菌(MRSA)的干预措施。
Cochrane Database Syst Rev. 2018 Jul 21;7(7):CD009650. doi: 10.1002/14651858.CD009650.pub4.
5
Pseudomonas aeruginosa Magnesium Transporter MgtE Inhibits Type III Secretion System Gene Expression by Stimulating Transcription.铜绿假单胞菌镁转运蛋白MgtE通过刺激转录来抑制III型分泌系统基因表达。
J Bacteriol. 2017 Oct 31;199(23). doi: 10.1128/JB.00268-17. Print 2017 Dec 1.
6
Oral anti-pseudomonal antibiotics for cystic fibrosis.用于囊性纤维化的口服抗假单胞菌抗生素。
Cochrane Database Syst Rev. 2016 Jul 14;7(7):CD005405. doi: 10.1002/14651858.CD005405.pub4.
7
Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.群体药代动力学及应用蒙特卡洛模拟评估目前推荐的囊性纤维化成年患者环丙沙星给药方案
Antimicrob Agents Chemother. 2001 Dec;45(12):3468-73. doi: 10.1128/AAC.45.12.3468-3473.2001.
8
Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis. Current practice and suggestions for future directions.囊性纤维化患者抗菌治疗的药代动力学优化。当前实践及未来方向建议。
Clin Pharmacokinet. 1998 Dec;35(6):437-59. doi: 10.2165/00003088-199835060-00003.
9
Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.环丙沙星:抗菌活性、药代动力学特性及治疗用途综述
Drugs. 1988 Apr;35(4):373-447. doi: 10.2165/00003495-198835040-00003.
10
Serum levels of ciprofloxacin after single oral doses in patients with septicemia.败血症患者单次口服剂量后环丙沙星的血清水平。
Eur J Clin Microbiol Infect Dis. 1989 Dec;8(12):1019-23. doi: 10.1007/BF01975162.